Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial

We compared the efficacy and safety of infliximab with intravenous immunoglobulin (IVIG), a standard therapy, in a phase 3 trial (NCT01596335) for Japanese patients with Kawasaki disease (KD) showing persistent fever after initial IVIG. Patients with initial IVIG-refractory KD, aged 1–10 years, rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Mori, Masaaki, Hara, Takuma, Kikuchi, Masako, Shimizu, Hiroyuki, Miyamoto, Tomoyuki, Iwashima, Satoru, Oonishi, Tatsuya, Hashimoto, Kunio, Kobayashi, Norimoto, Waki, Kenji, Suzuki, Yasuo, Otsubo, Yoshikazu, Yamada, Hiroshi, Ishikawa, Chikao, Kato, Taichi, Fuse, Shigeto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5792468/
https://www.ncbi.nlm.nih.gov/pubmed/29386515
http://dx.doi.org/10.1038/s41598-017-18387-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5792468/
https://www.ncbi.nlm.nih.gov/pubmed/29386515
http://dx.doi.org/10.1038/s41598-017-18387-7

Ejemplares similares